Compare Smith & Nephew plc (SNN) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Wix.Com Ltd — how do they compare? Smith & Nephew plc trades at $27.05 (market cap $11.10B), while Wix.Com Ltd trades at $75.18 (market cap $3.11B). The key difference: Smith & Nephew plc is far larger — about 3.6× Wix.Com Ltd's market cap, and Smith & Nephew plc pays a 2.95% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Wix.Com Ltd for 62 Days on average.
| SNN | WIX | |
|---|---|---|
Market Cap | $11.10B | $3.11B |
Volume | 1,051,703 | 809,286 |
Sector | Health | Technology |
52-Week High | $37.17 | $145.54 |
52-Week Low | $26.42 | $40.43 |
Typical Hold Time | 120 Days | 62 Days |
Enterprise Value | $14.13B | $4.19B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Wix.com (WIX) trades at $72.97, down 1.27% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth reaching $1.99B in 2025, though net income margin remains negative at -8.19%. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing. Multiple class action lawsuits filed in September 2026 create significant legal overhang.
While analyst consensus remains bullish with 63% buy ratings and $77 price target, the combination of negative cash flow trends, legal challenges, and high valuation multiples (P/E 62.84) presents substantial risk. The stock faces headwinds from operational execution challenges despite solid revenue growth fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
